Phase 1 data evaluating VRB-101, Verdiva Bio’s cAMP-biased oral GLP-1RA, provides proof of concept for potential once-weekly oral administration. Preclinical…
Miami, Florida, June 19, 2025 (GLOBE NEWSWIRE) -- BAY Miner has officially announced the launch of its new mobile mining application…
MONTRÉAL, June 19, 2025 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Company” or “Premier Health”), a…
Philadelphia, PA, June 17, 2025 (GLOBE NEWSWIRE) -- Crypto News: BCC Mining, the world's largest cloud mining platform, officially announced…
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…
ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical…
PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical…
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…
LOS ANGELES--(BUSINESS WIRE)--WhiteHawk Capital Partners: WhiteHawk Capital Partners has provided a $70 million senior secured term loan to an online…
STOCKHOLM, June 13, 2025 /PRNewswire/ -- The Curt Bergfors Foundation is honored to announce that NitroCapt was awarded the Food Planet…